or
forgot password

Metabolic Imaging: Predicting Histopathologic Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer


N/A
18 Years
N/A
Not Enrolling
Both
Rectal Cancer

Thank you

Trial Information

Metabolic Imaging: Predicting Histopathologic Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer


Inclusion Criteria:

- You must be diagnosed with locally advanced rectal cancer and have
chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a
standard treatment approach for this disease.

Exclusion Criteria:- You are ineligible for this study if you are pregnant or under the
age of 18 years old.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.

Outcome Time Frame:

not known

Safety Issue:

No

Principal Investigator

Albert Koong

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

REC0001

NCT ID:

NCT00394615

Start Date:

October 2003

Completion Date:

October 2005

Related Keywords:

  • Rectal Cancer
  • Rectal Neoplasms

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317